1PFE trade ideas
Pfizer got back on the rail Locally the trend has changed to the bullish side and price has returned inside of the channel. The bottom boundary of the channel has been tested successfully, and now I'm waiting the price to test the upper boundary of this channel. Currently, the price is moving inside the small rising channel and the bottom boundary of that channel works as a support.
Trade cancellation will occur in case if price would fix below 27.8 with 2 candles on daily basis.
Target is mentioned on chart.
DYOR
WDAY NASDAQ:WDAY
Short-Term (Hourly/Daily View):
Trend: Consolidation/Bearish with potential support retest.
Trade Direction: Consider shorting on any failed rally toward the $260 region or if the price breaks below the $240 area. Alternatively, look for long positions near the $240-$245 region with a tight stop loss if the price finds support at the 200-period EMA.
Long-Term (Weekly View):
Trend: Bullish on the weekly chart, with the trend intact but a potential pullback.
Trade Direction: Consider going long near the $240 level on any retracement towards the 20-period EMA. A break above $270 would indicate a continuation of the uptrend for a longer-term trade.
PFE (Y24.P3.E1). Sideways as part of wave 3 to 4Hi traders,
My thoughts on Pfizer to bottom out.
My level of interest is based on my common values for Elliott wave count based on a few assumptions. If it plans out, we will look for a long.
For now, expect a breakdown with this rising channel as the LH and LL overlap, bearish in nature.
All the best,
S.SAri
PFE . PfizerUS companies engaged in health technology sector
These US companies operate in the same sector, health technology. They're equipped with price, change, and other stats to help you get the most details. The list contains stocks for any strategy: giants with large caps like Eli Lilly and Company, top gainers like Portage Biotech Inc., and more. Filter the list and check companies' performance in a convenient way.
www.tradingview.com
$PFE | Allocation/Buy Trade | Market Exec |Technical Confluences:
- Price is in Oversold Conditions in D1 timeframe
- Price action bouncing off 150% Fibo Extension
- Price is trying to go back above the Interest Zone to give some bullish momentum to the stock
Fundamental Confluences:
-Regardless how bad the negative rumours are ongoing about the side-effects from Pfizer; they are still considered a strong market leader in the Pharma industry
- They had a good response on a testing of their recent respiratory drug
- Value?
----
Health sector in your Portfolio will never be wrong with the global aging population.
I am putting this trade on as either into my Long-Term Portfolio or Swing trade for $PFE.
Depending on how market develops, I may decide to hold this bag and allocate more into it at the 178% Fibo Extension levels or cut my Buy position as shown.
-----
Is Pfizer Trying to Turn?Pfizer has struggled for years, but some traders may see signs of a turn.
The first pattern on today’s chart is the pair of positive moves after stronger-than-expected earnings reports. Those may reflect improving fundamentals for the drugmaker.
Second, the 50-day simple moving average (SMA) had a “golden cross” above the 200-day SMA last month. Has the longer-term trend improved?
Next, PFE made a lower low on Tuesday versus Monday and a higher high. That “outside day” may be viewed as a potentially bullish reversal pattern.
Finally, stochastics turned up after hitting an oversold condition.
TradeStation has, for decades, advanced the trading industry, providing access to stocks, options and futures. See our Overview for more.
Past performance, whether actual or indicated by historical tests of strategies, is no guarantee of future performance or success. There is a possibility that you may sustain a loss equal to or greater than your entire investment regardless of which asset class you trade (equities, options or futures); therefore, you should not invest or risk money that you cannot afford to lose. Online trading is not suitable for all investors. View the document titled Characteristics and Risks of Standardized Options at www.TradeStation.com . Before trading any asset class, customers must read the relevant risk disclosure statements on www.TradeStation.com . System access and trade placement and execution may be delayed or fail due to market volatility and volume, quote delays, system and software errors, Internet traffic, outages and other factors.
Securities and futures trading is offered to self-directed customers by TradeStation Securities, Inc., a broker-dealer registered with the Securities and Exchange Commission and a futures commission merchant licensed with the Commodity Futures Trading Commission). TradeStation Securities is a member of the Financial Industry Regulatory Authority, the National Futures Association, and a number of exchanges.
TradeStation Securities, Inc. and TradeStation Technologies, Inc. are each wholly owned subsidiaries of TradeStation Group, Inc., both operating, and providing products and services, under the TradeStation brand and trademark. When applying for, or purchasing, accounts, subscriptions, products and services, it is important that you know which company you will be dealing with. Visit www.TradeStation.com for further important information explaining what this means.
Classic Wyckoff accumulation. Markup phase coming ! This video is an analysis on the Wyckoff accumulation setup. All aspects of the method are being checked off so it's just a matter of time before we get a breakout due to a "catalyst in the news". Obviously, good news for the vaccine sector will probably be bad news for the overall market.
PFE Long PositionHi traders,
The price has been in the uptrend since April 2024 and we expect a pullback to retest the upsloping support level.which would be our entry.
Our target for this position would be at the upsloping resistance.
Good luck
$PFE Pfizer. Rounded bottom breakoutNice rounded bottom breakout and retest @ $29,30 level. If this level holds the target would be $33,50. 15% Upside on a good dividend payer.
PFE is it completed the Accumulation and Going to Fly ?! It is the first time to break out the wide range since DEC 2023
Now We are in Phase E ( Trading outside the Range) - Wyckoff Method
Supply showing Effort with no result
Demand has Increased
Also there is upcoming earning
so, Is the accumulation phase has completed and we are going to 🚀 ?!
TP 01 : 34.71
TP 02: 37.17
SL: 29.30
I am Just sharing insights and market trends for learning and growing every day and it is not financial advice.
Short Chance. PFIZER (short term) Technical
Earning are deceasing.
I see a lower price/lower earnings cycle popup.
Price is high compaired to a normal reaction for lower earnings. Big buyer drives up the price but this one does not drive the price up. So I think it will reverse when the buyer leaves.
Risk reward short seems higher for me at this point. First Close after the 10D VWAP should be a trigger.
Fundamental
Not in image for this trade horizon.
Long PilledOnce-a-day obesity pill en route. Expect the share price to swell with the anticipation over the years, to the tune of 200%.
Standard 1.618 long term extensions all but guaranteed.
PERFECT TIME TO BUY. $PFE to $32 before Next Earning The falling wedge is a bullish price formation that tells a tale of the stock where bulls are gearing up for a new rally.
+ NYSE:PFE is trading below my estimate of fair value ($68.47). OVERSOLD!
+ Their Earning is expected to return to the $9-10 billion range (Pre-Covid). The current earning is 2.13 billion.
+ Paxlovid, Prevnar, Elliquis, Ibrance, Xeljanz, Enbrel and Zithromax/Zmax continue to be the most effecitive medications.
+ Pfizer, a company that pays dividends, currently has a yield of 6.21%. I have faith in my chart analysis, however, even if there are inconsistencies, dividends will continue to be distributed, which solidifies its attractiveness as a long-term investment opportunity.
Risk-Free & East Gain
PFE - our Long Call materializesOur recent recommended top pick from Healthcare sector: PFE: released better than expected financial results; raised full year guidance;
The company’s earnings per share (EPS) in the second quarter stood at $0.60, surpassing the consensus estimate of $0.46. Revenue came in at $13.3 billion, also above the projected $13.03 billion.
Pfizer reported adjusted research and development expenses of $2.67 billion for the period, compared to the estimated $2.83 billion.
Looking forward, the pharmaceutical giant now projects FY2024 EPS of $2.45 to $2.65, up from the previous guidance of $2.15 to $2.35, and above the consensus estimate of $2.38.
price levels to trade PFE after its earningCertainly! **Pfizer** has been actively advancing its gene therapy pipeline, particularly in the field of hemophilia. Here are some key developments:
1. **Giroctocogene fitelparvovec**:
- Pfizer announced positive topline results from the **Phase 3 AFFINE study** evaluating giroctocogene fitelparvovec. This investigational gene therapy targets **hemophilia A** in adults with moderately severe to severe forms of the condition.
- Key findings:
- Achieved its primary objective of **non-inferiority** and **superiority** compared to routine Factor VIII (FVIII) replacement prophylaxis treatment.
- Demonstrated a statistically significant reduction in mean total annualized bleeding rate (ABR) compared to the pre-infusion period.
- Most participants maintained FVIII activity >5% at 15 months post-infusion.
- Generally well-tolerated, with no impact on efficacy and safety results¹.
- Notably, Pfizer also received FDA approval for **Beqvez**, a gene therapy for **hemophilia B**.
- Additionally, regulatory submissions for **marstacimab** as a potential treatment for both hemophilia A and B are underway in the U.S. and Europe².
2. **Other Gene Therapy Programs**:
- Pfizer currently has three Phase 3 programs investigating gene therapy in populations with high unmet needs:
- **Hemophilia B**
- **Hemophilia A**
- **Duchenne muscular dystrophy**³.
Pfizer's commitment to advancing gene therapies holds great promise for patients worldwide. 🌟🧬⁴⁵ 🚀
Source: Conversation with Copilot, 7/30/2024
(1) Pfizer Announces Positive Topline Results From Phase 3 Study of .... www.pfizer.com
(2) Pfizer Hemophilia Gene Therapy Meets Phase 3 Goals, But Its Success .... medcitynews.com
(3) Pfizer Announces Positive Top-Line Results from Phase 3 Study of .... www.pfizer.com
(4) Pfizer Pipeline. cdn.pfizer.com
(5) New Drug Development Pipeline: Pfizer's Medicine, Vaccine Discovery .... www.pfizer.com
White oscillation range rises and breaks throughWhite oscillation range rises and breaks through
There are also yellow oscillation intervals and blue downward channels
$PFE long ideaSome significant support here on the weekly chart. I got in a few days ago.. Risk reward ratio worth the long here. Always manage risk so you can live to trade another day! This is not financial advice of course. Please do your own research & Happy Trading!
PFE LongPFE as market a local bottom in my opinion. It breached the lows of a long consolidation and reversed soon after. It also seems to be forming a triangle on the monthly timeframe
PFEPFE consolidates after a flat correction. Larger frame analysis is in the updates below.
Tracking this stock for a long time. Now its time to go up
Manage your risk. Don't overconcentrate individual positions, let them concentrate themselves as the winners grow.
PFE breakout PossibleHolding strong support
29 above trendline breakout Possible
31/33/36 can test soon
Pfizer (PFE) AnalysisOverview:**
Pfizer Inc. (PFE) has been in a prolonged downtrend but is showing signs of potential recovery. The recent chart indicates a bounce from the lows, with key technical indicators suggesting a possible reversal.
**Technical Analysis:**
1. **Fibonacci Retracement Levels**:
- The chart shows Fibonacci retracement levels drawn from the recent high to the low. The stock has rebounded from the lower levels and is currently testing the 23.6% retracement level around $29.50. A sustained break above this level could target the next resistance levels at $32 and $35.
2. **Moving Averages**:
- The stock has moved above the short-term moving averages (indicated by the green and blue lines), which suggests bullish momentum. If it can maintain above these levels, it could attract more buying interest.
3. **MACD and RSI**:
- The MACD indicator shows a bullish crossover, and the histogram has turned positive, indicating increasing bullish momentum.
- The RSI is rising from oversold territory, currently at 87.03, which suggests strong buying pressure but also warrants caution as it nears overbought levels.
**Fundamental Perspective:**
- **Recent Developments**:
Pfizer's ongoing developments in its drug pipeline, including advancements in COVID-19 treatments and vaccines, continue to provide long-term growth potential. Investors should keep an eye on upcoming earnings reports and updates on key products.
- **Valuation**
The current price level may represent a value opportunity given Pfizer's strong balance sheet and consistent dividend payments. The company has a history of generating significant free cash flow, which supports its ability to invest in new research and return capital to shareholders.
**Conclusion:**
Pfizer appears to be at a crucial juncture, with technical indicators suggesting a potential trend reversal. Investors should monitor the $29.50 level for a possible breakout and consider the broader market conditions and Pfizer’s upcoming announcements for further confirmation of the bullish trend.
**Risk Management:**
- Set stop-loss orders below recent lows to manage downside risk.
- Consider scaling into the position to mitigate the impact of volatility.
**Disclaimer**: This analysis is for informational purposes only and should not be considered as financial advice.
Dr SAUD
Pfizer Big buy opportunity!After long time of sell pfizer has reached a really good buy opportunity!
buy now for a 20.59 R/R
